Summary of new onset diseasesa | HPV vaccine total (N = 47,075) | Comparator total (N = 48,595) | Risk ratiof total [95% CI] | Risk ratiof MSC [95% CI] | Risk ratiof NMH [95% CI] |
---|---|---|---|---|---|
Total | |||||
Participants with new onset diseasesb | 14,258 | 14,014 | 0.99 [0.97, 1.02] | 0.98 [0.90, 1.06] | 1.00 [0.97, 1.03] |
Follow-upc | 2296 | 2365 | 0.98 [0.94, 1.01] | Not applicable | 0.98 [0.94, 1.01] |
Number of MedDRA-classified new onset diseasesb | 47,474 | 46,662 | Not applicable | Not applicable | Not applicable |
Medically significant conditions (MSC)d | 7882 (17%) | 7994 (17%) | Not applicable | Not applicable | Not applicable |
New medical history (NMH)e | 39,592 (83%) | 38,668 (83%) | Not applicable | Not applicable | Not applicable |
Most common new onset diseases (MedDRA-preferred terms, n = participants) | |||||
MSC | |||||
Depression | 443 | 432 | 1.02 [0.89, 1.16] | 1.02 [0.85, 1.23] | 1.01 [0.84, 1.22] |
Genitourinary tract gonococcal infection | 149 | 162 | 0.92 [0.74, 1.15] | 0.91 [0.73, 1.14] | 1.15 [0.37, 3.52] |
Gynaecological chlamydia infection | 1409 | 1512 | 0.93 [0.87, 1.00] | 0.95 [0.88, 1.03] | 0.87 [0.76, 1.00] |
NMH | |||||
Vaginal candidiasis | 1297 | 1359 | 0.95 [0.89, 1.02] | Not applicable | 0.95 [0.89, 1.02] |
Vaginitis bacterial | 1185 | 1204 | 0.98 [0.91, 1.06] | Not applicable | 0.98 [0.91, 1.06] |
Urinary tract infection | 1023 | 1086 | 0.93 [0.86, 1.01] | 0.33 [0.01, 8.19] | 0.93 [0.86, 1.02] |
New onset diseases most increased by the HPV vaccines (MedDRA-preferred terms, n = participants) | |||||
MSC | |||||
Abdominal pain | 433 | 374 | 1.21 [0.98, 1.50] | 1.38 [1.00, 1.92] | 1.17 [0.87, 1.57] |
Back pain | 397 | 336 | 1.15 [1.00, 1.33] | 1.40 [1.05, 1.86] | 1.08 [0.91, 1.28] |
Headache | 771 | 693 | 1.06 [0.92, 1.22] | 1.29 [0.75, 2.24] | 1.04 [0.93, 1.15] |
NMH | |||||
Amenorrhoea | 394 | 359 | 1.09 [0.87, 1.37] | 0.66 [0.38, 1.15] | 1.17 [0.93, 1.48] |
Headache | 771 | 693 | 1.06 [0.92, 1.22] | 1.29 [0.75, 2.24] | 1.04 [0.93, 1.15] |
Joint sprain | 113 | 83 | 1.18 [0.80, 1.75] | 0.60 [0.29, 1.22] | 1.45 [0.94, 2.24] |
New onset diseases most decreased by the HPV vaccines (MedDRA-preferred terms, n = participants) | |||||
MSC | |||||
Cystitis | 480 | 502 | 0.93 [0.77, 1.09] | 0.65 [0.44, 0.96] | 0.99 [0.87, 1.13] |
Gynaecological chlamydia infection | 1409 | 1512 | 0.93 [0.87, 1.00] | 0.95 [0.88, 1.03] | 0.87 [0.76, 1.00] |
Type 2 diabetes mellitus | 31 | 47 | 0.89 [0.38, 2.09] | 0.62 [0.32, 1.20] | 3.00 [0.47, 19.02] |
NMH | |||||
Urinary tract infection | 1023 | 1086 | 0.93 [0.86, 1.01] | 0.33 [0.01, 8.19] | 0.93 [0.86, 1.02] |
Vaginal candidiasis | 1297 | 1359 | 0.95 [0.89, 1.02] | Not applicable | 0.95 [0.89, 1.02] |
Vaginal infection | 369 | 420 | 0.87 [0.76, 1.00] | Not applicable | 0.87 [0.76, 1.00] |